Fibronox
Organisation
People
President & ceo, 25 Aug 2025, reporter.nih.gov
10 May 2024, reporter.nih.gov
Grants and prizes
National Heart, Lung, and Blood Institute
R44, Advanced Pre-clinical development of Nox4 inhibitors for Pulmonary Fibrosis, R44HL172475, US$1.1m, 2024–2027, 25 Aug 2025, reporter.nih.gov
National Heart, Lung, and Blood Institute
R41, Repurposing of FDA-approved Nrf2 Activators as a Novel Inhaled Therapy for Pulmonary Fibrosis, R41HL174346, US$286.7k, 2024–2027, 10 May 2024, reporter.nih.gov